人体主要外分泌腺导管癌的诊疗与预后

doi:10.3760/cma.j.cn371439-20210602-00087

摘要/Abstract

摘要：

外分泌腺导管癌是外分泌腺恶性肿瘤重要的组成部分,包括乳腺浸润性导管癌、唾液腺导管癌、胰腺导管腺癌、胆管癌等,这类疾病多具有一定的侵袭性,恶性程度较高,危害人体健康,早期筛查诊断是外分泌腺导管癌预后良好的关键。不同的外分泌腺导管癌之间也具有一定的联系,其分子生物学特征、病理特征与分子机制具有相似之处。手术切除治疗伴辅助放化疗是目前外分泌腺导管癌常用的治疗方法,同时其相关的靶向治疗、免疫治疗位点也可以相互借鉴,人表皮生长因子受体-2(HER-2)及同家族标志物已成为乳腺导管癌和唾液腺导管癌的靶向治疗位点,针对程序性死亡配体1(PD-L1)位点的免疫治疗在许多研究中也有涉及,但尚无明确结论。

关键词: 导管癌, 诊断, 分子靶向治疗, 预后

Abstract:

Exocrine ductal carcinoma is an important part of malignant tumors of exocrine glands, including invasive breast ductal carcinoma, salivary duct carcinoma, pancreatic ductal adenocarcinoma and cholangiocarcinoma. Most of these diseases are aggressive, highly malignant and endanger human health. Early detection and diagnosis are the key to a good prognosis for exocrine ductal carcinoma. Different exocrine ductal carcinomas also have certain connections, and their molecular biological characteristics, pathological characteristics and molecular mechanisms have similarities. Surgical resection combined with adjuvant radiotherapy and chemotherapy is currently a common treatment method for exocrine ductal carcinoma. At the same time, its related targeted therapy and immunotherapy sites can also learn from each other. Human epidermal growth factor receptor-2 (HER-2) and the family markers have become breast ductal carcinoma and salivary duct carcinoma targeted therapy sites, and immunotherapy at programmed death ligand 1 (PD-L1) sites has also been involved in many studies, but there is no clear conclusion yet.

Key words: Ductal carcinoma, Diagnose, Molecular targeted therapy, Prognosis

马平川, 李春洁, 李龙江. 人体主要外分泌腺导管癌的诊疗与预后[J]. 国际肿瘤学杂志, 2021, 48(8): 449-455.

Ma Pingchuan, Li Chunjie, Li Longjiang. Diagnosis, treatment and prognosis of human major exocrine ductal carcinoma[J]. Journal of International Oncology, 2021, 48(8): 449-455.

参考文献 62

[1]	Sinn H, Kreipe H. A brief overview of the WHO classification of breast tumors, 4th edition, focusing on issues and updates from the 3rd edition[J]. Breast Care (Basel), 2013,8(2):149-154. DOI: 10.1159/000350774. doi: 10.1159/000350774
[2]	Yi M, Mittendorf EA, Cormier JN, et al. Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system[J]. J Clin Oncol, 2011,29(35):4654-4661. DOI: 10.1200/JCO.2011.38.3174. doi: 10.1200/JCO.2011.38.3174
[3]	Choi G, Woo OH, Shin HS, et al. Comparison of two-dimensional synthesized mammogram (2DSM) and conventional full-field digital mammogram (FFDM) for evaluation of breast cancer[J]. Clin Imaging, 2017,43:170-174. DOI: 10.1016/j.clinimag.2017.03.004. doi: 10.1016/j.clinimag.2017.03.004
[4]	Payandeh M, Sadeghi M, Sadeghi E, et al. Clinicopathology figures and long-term effects of tamoxifen plus radiation on survival of women with invasive ductal carcinoma and triple negative breast cancer[J]. Asian Pac J Cancer Prev, 2015,16(12):4863-4867. DOI: 10.7314/apjcp.2015.16.12.4863. doi: 10.7314/apjcp.2015.16.12.4863
[5]	Mohanty SK, La J, Gordon OK, et al. BRCA-mutated invasive breast carcinomas: immunohistochemical analysis of insulin-like growth factor Ⅱ mRNA-binding protein (IMP3), cytokeratin 8/18, and cytokeratin 14[J]. Breast J, 2015,21(6):596-603. DOI: 10.1111/tbj.12494. doi: 10.1111/tbj.12494
[6]	Diéras V, Miles D, Verma S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2017,18(6):732-742. DOI: 10.1016/S1470-2045(17)30312-1. doi: 10.1016/S1470-2045(17)30312-1
[7]	von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer[J]. N Engl J Med, 2017,377(2):122-131. DOI: 10.1056/NEJMoa1703643. doi: 10.1056/NEJMoa1703643
[8]	Hurvitz SA, Martin M, Symmans WF, et al. Neoadjuvant trastuzu-mab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial[J]. Lancet Oncol, 2018,19(1):115-126. DOI: 10.1016/S1470-2045(17)30716-7. doi: S1470-2045(17)30716-7 pmid: 29175149
[9]	Witkiewicz AK, Cox D, Knudsen ES. CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models[J]. Genes Cancer, 2014,5:261-272. DOI: 10.18632/genesandcancer.24. doi: 10.18632/genesandcancer.24 pmid: 25221644
[10]	Gianni L, Bisagni G, Colleoni M, et al. Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study[J]. Lancet Oncol, 2018,19(2):249-256. DOI: 10.1016/S1470-2045(18)30001-9. doi: S1470-2045(18)30001-9 pmid: 29326029
[11]	Luo J, Feng J, Wen Q, et al. Elevated expression of IRS-1 associates with phosphorylated Akt expression and predicts poor prognosis of breast invasive ductal carcinoma[J]. Hum Pathol, 2018,79:9-17. DOI: 10.1016/j.humpath.2018.03.003. doi: 10.1016/j.humpath.2018.03.003
[12]	Hurvitz SA, Andre F, Jiang Z, et al. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial[J]. Lancet Oncol, 2015,16(7):816-829. DOI: 10.1016/S1470-2045(15)00051-0. doi: 10.1016/S1470-2045(15)00051-0 pmid: 26092818
[13]	Jain S, Shah AN, Santa-Maria CA, et al. Phase Ⅰ study of alpeli-sib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy[J]. Breast Cancer Res Treat, 2018,171(2):371-381. DOI: 10.1007/s10549-018-4792-0. doi: 10.1007/s10549-018-4792-0
[14]	Cochrane DR, Bernales S, Jacobsen BM, et al. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide[J]. Breast Cancer Res, 2014,16(1):R7. DOI: 10.1186/bcr3599. doi: 10.1186/bcr3599
[15]	Gianni L, Baselga J, Eiermann W, et al. Phase Ⅲ trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary syste-mic therapy: European Cooperative Trial in Operable Breast Cancer[J]. J Clin Oncol, 2009,27(15):2474-2481. DOI: 10.1200/JCO.2008.19.2567. doi: 10.1200/JCO.2008.19.2567 pmid: 19332727
[16]	Bertucci F, Gonçalves A. Immunotherapy in breast cancer: the emerging role of PD-1 and PD-L1[J]. Curr Oncol Rep, 2017,19(10):64. DOI: 10.1007/s11912-017-0627-0. doi: 10.1007/s11912-017-0627-0
[17]	Tonellotto F, Bergmann A, de Souza Abrahão K, et al. Impact of number of positive lymph nodes and lymph node ratio on survival of women with node-positive breast cancer[J]. Eur J Breast Health, 2019,15(2):76-84. DOI: 10.5152/ejbh.2019.4414. doi: 10.5152/ejbh.2019.4414 pmid: 31001608
[18]	陈余英, 周小花, 陈晓文, 等. 乳腺浸润性导管癌中ER、PR、Her-2、Ki-67表达与病理特征及预后的相关性[J]. 医学信息, 2020,33(1):68-71. DOI: 10.3969/j.issn.1006-1959.2020.01.022. doi: 10.3969/j.issn.1006-1959.2020.01.022
[19]	Breinholt H, Elhakim MT, Godballe C, et al. Salivary duct carcinoma: a Danish national study[J]. J Oral Pathol Med, 2016,45(9):664-671. DOI: 10.1111/jop.12426. doi: 10.1111/jop.12426 pmid: 26822194
[20]	Otsuka K, Imanishi Y, Tada Y, et al. Clinical outcomes and prognostic factors for salivary duct carcinoma: a multi-institutional analysis of 141 patients[J]. Ann Surg Oncol, 2016,23(6):2038-2045. DOI: 10.1245/s10434-015-5082-2. doi: 10.1245/s10434-015-5082-2
[21]	Heřman J, Sedláčková Z, Fürst T, et al. The role of ultrasound and shear-wave elastography in evaluation of cervical lymph nodes[J]. Biomed Res Int, 2019,2019:4318251. DOI: 10.1155/2019/4318251. doi: 10.1155/2019/4318251 pmid: 31183367
[22]	Wu WL, Wang CL, Li D, et al. Multiphase contrast-enhanced computed tomography imaging features of salivary duct carcinoma: diffe-rentiation from other salivary gland malignancies[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2019,128(5):543-551. DOI: 10.1016/j.oooo.2019.05.011. doi: 10.1016/j.oooo.2019.05.011
[23]	Skálová A, Stenman G, Simpson RHW, et al. The role of molecular testing in the differential diagnosis of salivary gland carcinomas[J]. Am J Surg Pathol, 2018,42(2):e11-e27. DOI: 10.1097/PAS.0000000000000980. doi: 10.1097/PAS.0000000000000980
[24]	Gilbert MR, Sharma A, Schmitt NC, et al. A 20-year review of 75 cases of salivary duct carcinoma[J]. JAMA Otolaryngol Head Neck Surg, 2016,142(5):489-495. DOI: 10.1001/jamaoto.2015.3930. doi: 10.1001/jamaoto.2015.3930
[25]	Cracchiolo JR, Shaha AR. Parotidectomy for parotid cancer[J]. Otolaryngol Clin North Am, 2016,49(2):415-424. DOI: 10.1016/j.otc.2015.10.007. doi: 10.1016/j.otc.2015.10.007
[26]	Xiao CC, Zhan KY, White-Gilbertson SJ, et al. Predictors of nodal metastasis in parotid malignancies: a national cancer data base study of 22,653 patients[J]. Otolaryngol Head Neck Surg, 2016,154(1):121-130. DOI: 10.1177/0194599815607449. doi: 10.1177/0194599815607449
[27]	Qian K, Di L, Guo K, et al. Cervical lymph node metastatic status and adjuvant therapy predict the prognosis of salivary duct carcinoma[J]. J Oral Maxillofac Surg, 2018,76(7):1578-1586. DOI: 10.1016/j.joms.2018.01.033. doi: 10.1016/j.joms.2018.01.033
[28]	Boon E, van Boxtel W, Buter J, et al. Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: a nationwide case series of 35 patients in The Netherlands[J]. Head Neck, 2018,40(3):605-613. DOI: 10.1002/hed.25035. doi: 10.1002/hed.25035
[29]	Wasano K, Sakurai K, Kawasaki T, et al. Acquisition of resistance to androgen deprivation therapy in salivary duct carcinoma: a case report[J]. Rare Tumors, 2018,10:1359648275. DOI: 10.1177/2036361318798867. doi: 10.1177/2036361318798867
[30]	Gibo T, Sekiguchi N, Gomi D, et al. Targeted therapy with trastuzumab for epidermal growth factor receptor 2 (HER2)-positive advanced salivary duct carcinoma: a case report[J]. Mol Clin Oncol, 2019,11(2):111-115. DOI: 10.3892/mco.2019.1875. doi: 10.3892/mco.2019.1875
[31]	Takahashi H, Tada Y, Saotome T, et al. Phase Ⅱ trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma[J]. J Clin Oncol, 2019,37(2):125-134. DOI: 10.1200/JCO.18.00545. doi: 10.1200/JCO.18.00545 pmid: 30452336
[32]	Lin VTG, Nabell LM, Spencer SA, et al. First-line treatment of widely metastatic BRAF-mutated salivary duct carcinoma with combined BRAF and MEK inhibition[J]. J Natl Compr Canc Netw, 2018,16(10):1166-1170. DOI: 10.6004/jnccn.2018.7056. doi: 10.6004/jnccn.2018.7056
[33]	Johnston ML, Huang SH, Waldron JN, et al. Salivary duct carcinoma: treatment, outcomes, and patterns of failure[J]. Head Neck, 2016: E820-E826. DOI: 10.1002/hed.24107. doi: 10.1002/hed.24107
[34]	Mifsud M, Sharma S, Leon M, et al. Salivary duct carcinoma of the parotid: outcomes with a contemporary multidisciplinary treatment approach[J]. Otolaryngol Head Neck Surg, 2016,154(6):1041-1046. DOI: 10.1177/0194599816636812. doi: 10.1177/0194599816636812
[35]	Santana T, Pavel A, Martinek P, et al. Biomarker immunoprofile and molecular characteristics in salivary duct carcinoma: clinicopa-thological and prognostic implications[J]. Hum Pathol, 2019,93:37-47. DOI: 10.1016/j.humpath.2019.08.009. doi: 10.1016/j.humpath.2019.08.009
[36]	Du L, Wang-Gillam A. Trends in neoadjuvant approaches in pancreatic cancer[J]. J Natl Compr Canc Netw, 2017,15(8):1070-1077. DOI: 10.6004/jnccn.2017.0134. doi: 10.6004/jnccn.2017.0134
[37]	Baliyan V, Kordbacheh H, Parakh A, et al. Response assessment in pancreatic ductal adenocarcinoma: role of imaging[J]. Abdom Radiol (NY), 2018,43(2):435-444. DOI: 10.1007/s00261-017-1434-7. doi: 10.1007/s00261-017-1434-7 pmid: 29243123
[38]	Shrikhande SV, Barreto SG, Goel M, et al. Multimodality imaging of pancreatic ductal adenocarcinoma: a review of the literature[J]. HPB (Oxford), 2012,14(10):658-668. DOI: 10.1111/j.1477-2574.2012.00508.x. doi: 10.1111/j.1477-2574.2012.00508.x
[39]	Park HJ, Jang KM, Song KD, et al. Value of unenhanced MRI with diffusion-weighted imaging for detection of primary small (≤20 mm) solid pancreatic tumours and prediction of pancreatic ductal adenocarcinoma[J]. Clin Radiol, 2017,72(12):1076-1084. DOI: 10.1016/j.crad.2017.07.009. doi: S0009-9260(17)30382-3 pmid: 28784320
[40]	Izumo W, Higuchi R, Furukawa T, et al. Evaluation of preoperative prognostic factors in patients with resectable pancreatic ductal adenocarcinoma[J]. Scand J Gastroenterol, 2019,54(6):780-786. DOI: 10.1080/00365521.2019.1624816. doi: 10.1080/00365521.2019.1624816
[41]	Komatsu S, Ichikawa D, Miyamae M, et al. Malignant potential in pancreatic neoplasm; new insights provided by circulating miR-223 in plasma[J]. Expert Opin Biol Ther, 2015,15(6):773-785. DOI: 10.1517/14712598.2015.1029914. doi: 10.1517/14712598.2015.1029914 pmid: 25819175
[42]	Kinugasa H, Nouso K, Miyahara K, et al. Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer[J]. Cancer, 2015,121(13):2271-2280. DOI: 10.1002/cncr.29364. doi: 10.1002/cncr.29364 pmid: 25823825
[43]	Khushman M, Patel GK, Laurini JA, et al. Exosomal markers (CD63 and CD9) expression and their prognostic significance using immunohistochemistry in patients with pancreatic ductal adenocarcinoma[J]. J Gastrointest Oncol, 2019,10(4):695-702. DOI: 10.21037/jgo.2018.07.02. doi: 10.21037/jgo.2018.07.02 pmid: 31392050
[44]	Hammel P, Huguet F, van Laethem J, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial[J]. JAMA, 2016,315(17):1844-1853. DOI: 10.1001/jama.2016.4324. doi: 10.1001/jama.2016.4324
[45]	Reni M, Cereda S, Mazza E, et al. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemci-tabine-containing chemotherapy[J]. Am J Clin Oncol, 2008,31(2):145-150. DOI: 10.1097/COC.0b013e31814688f7. doi: 10.1097/COC.0b013e31814688f7
[46]	Chawla A, Molina G, Pak LM, et al. Neoadjuvant therapy is associated with improved survival in borderline-resectable pancreatic can-cer[J]. Ann Surg Oncol, 2020,27(4):1191-1200. DOI: 10.1245/s10434-019-08087-z. doi: 10.1245/s10434-019-08087-z pmid: 31802297
[47]	O'Neil BH, Scott AJ, Ma WW, et al. A phase Ⅱ/Ⅲ randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer[J]. Ann Oncol, 2015,26(9):1923-1929. DOI: 10.1093/annonc/mdv264. doi: S0923-7534(19)31765-X pmid: 26091808
[48]	Zhang Y, Velez-Delgado A, Mathew E, et al. Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer[J]. Gut, 2017,66(1):124-136. DOI: 10.1136/gutjnl-2016-312078. doi: 10.1136/gutjnl-2016-312078
[49]	Krasinskas AM. Cholangiocarcinoma[J]. Surg Pathol Clin, 2018,11(2):403-429. DOI: 10.1016/j.path.2018.02.005. doi: S1875-9181(18)30005-9 pmid: 29751883
[50]	Joo I, Lee JM, Yoon JH. Imaging diagnosis of intrahepatic and perihilar cholangiocarcinoma: recent advances and challenges[J]. Radiology, 2018,288(1):7-13. DOI: 10.1148/radiol.2018171187. doi: 10.1148/radiol.2018171187
[51]	Li Y, Huang Y, Chen J. Diagnostic value of serum biomarkers for intrahepatic cholangiocarcinoma[J]. J Coll Physicians Surg Pak, 2019,29(10):962-966. DOI: 10.29271/jcpsp.2019.10.962. doi: 10.29271/jcpsp.2019.10.962
[52]	Wirth TC, Vogel A. Surveillance in cholangiocellular carcinoma[J]. Best Pract Res Clin Gastroenterol, 2016,30(6):987-999. DOI: 10.1016/j.bpg.2016.11.001. doi: 10.1016/j.bpg.2016.11.001
[53]	Chun YS, Javle M. Systemic and adjuvant therapies for intrahepatic cholangiocarcinoma[J]. Cancer Control, 2017,24(3):1-7. DOI: 10.1177/1073274817729241. doi: 10.1177/1073274817729241
[54]	El-Khoueiry AB, Rankin C, Siegel AB, et al. S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma[J]. Br J Cancer, 2014,110(4):882-887. DOI: 10.1038/bjc.2013.801. doi: 10.1038/bjc.2013.801
[55]	Mantel HT, Westerkamp AC, Adam R, et al. Strict selection alone of patients undergoing liver transplantation for hilar cholangiocarcinoma is associated with improved survival[J]. PLoS One, 2016,11(6):e156127. DOI: 10.1371/journal.pone.0156127. doi: 10.1371/journal.pone.0156127
[56]	Phan K, Kim L, Lim P, et al. A case report of temple squamoid eccrine ductal carcinoma: a diagnostic challenge beneath the tip of the iceberg[J]. Dermatol Ther, 2020,33(2):e13213. DOI: 10.1111/dth.13213. doi: 10.1111/dth.13213
[57]	van der Horst MP, Garcia-Herrera A, Markiewicz D, et al. Squa-moid eccrine ductal carcinoma: a clinicopathologic study of 30 cases[J]. Am J Surg Pathol, 2016,40(6):755-760. DOI: 10.1097/PAS.0000000000000599. doi: 10.1097/PAS.0000000000000599
[58]	Frouin E, Vignon-Pennamen MD, Balme B, et al. Anatomoclinical study of 30 cases of sclerosing sweat duct carcinomas (microcystic adnexal carcinoma, syringomatous carcinoma and squamoid eccrine ductal carcinoma)[J]. J Eur Acad Dermatol Venereol, 2015,29(10):1978-1994. DOI: 10.1111/jdv.13127. doi: 10.1111/jdv.13127 pmid: 25873411
[59]	Weis E, Rootman J, Joly TJ, et al. Epithelial lacrimal gland tumors: pathologic classification and current understanding[J]. Arch Ophthalmol, 2009,127(8):1016-1028. DOI: 10.1001/archophthalmol.2009.209. doi: 10.1001/archophthalmol.2009.209
[60]	See TRO, Stålhammar G, Tang T, et al. Primary ductal adenocarcinoma of the lacrimal gland: a review and report of five cases[J]. Surv Ophthalmol, 2020,65(3):371-380. DOI: 10.1016/j.survophthal.2019.11.002. doi: 10.1016/j.survophthal.2019.11.002
[61]	Everett LA, Copperman TS, Kersten RC. A case of lacrimal gland ductal carcinoma with regional lymph node metastasis[J]. Ophthalmic Plast Reconstr Surg, 2019,35(5):e118-e121. DOI: 10.1097/IOP.0000000000001447. doi: 10.1097/IOP.0000000000001447
[62]	Zhu MM, Cui HG, Teng XD. GCDFP-15, AR, and Her-2 as biomarkers for primary ductal adenocarcinoma of the lacrimal gland: a Chinese case and literature review[J]. Onco Targets Ther, 2015,8:1017-1024. DOI: 10.2147/OTT.S82168. doi: 10.2147/OTT.S82168